A Seeking Alpha analyst has upgraded TransMedics (NASDAQ:TMDX) to Strong Buy, citing expected revenue growth of around 25% in 2026 and free cash flow breakeven by late 2026 or early 2027. The firm is seen as over the peak of its capital expenditure cycle, with margins targeting 30% by 2028. The analyst holds a long position in the stock.
TransMedics (TMDX), a medical technology company, is positioned for accelerating growth according to a recent Seeking Alpha analysis published on March 16, 2026. The article highlights revenue expansion around 25% in 2026 and achievement of free cash flow breakeven by late 2026 or early 2027. It notes that the company has passed the crest of its capex cycle, with easing investment pressures set to support margin expansion toward a 30% target by 2028. The analyst remains bullish provided revenue growth stays above 20% year-over-year, despite concerns over a weak balance sheet and potential 15% shareholder dilution in 2026. The market's short-term focus is said to overlook TMDX's long-term growth trajectory, robust operating leverage, and AI-immune business model. The author discloses a beneficial long position in TMDX shares through stock ownership, options, or other derivatives and expresses personal opinions without compensation beyond Seeking Alpha contributions. No business relationship exists with the company. Past performance is not indicative of future results, and the views do not necessarily reflect Seeking Alpha's stance.